Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 6, 03 August 2023
Open
Access | Article
Immune escape mechanism of PD-1/PD-L1 in non-small-cell lung cancer(NSCLC) and its related drug treatment
* Author to whom correspondence should be addressed.
Abstract
In recent years, a variety of treatment methods for Non-small cell lung cancer (NSCLC) have been used, but most of them fail to show significant effect due to the late stage of diagnosis. At present, immunotherapy has become a new way of tumor therapy and attracted wide attention, among which programmed death molecule-1(PD-1) and programmed death ligand-1(PD-L1) have been proved to relate to immune escape in NSCLC, and relevant clinical drugs have shown a clear therapeutic effect. The related drugs can relieve the immune tolerance by blocking the pathway, and play a role in tumor killing. There are now various related drugs. Here, I review the progresses of the mechanistic role of PD-1 pathway in the tumor immune escape and effect of related drugs therapy.
Keywords
NSCLC, PD-1, PD-L1, immune escape, immunotherapy
References
1. Shen, X., Huang, S., Xiao, H., et al. (2023) Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. European Journal of Hospital Pharmacy, 30(1):3-8.
2. Li, Y., Brendel, M., Wu, N., et al. (2022) Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer. Scientific Reports, 12(1):17670.
3. Chao, C., Di, D., Wang, M., et al. (2022) Identifying octogenarians with non-small cell lung cancer who could benefit from surgery: A population-based predictive model. Front Surg, 28(9):972014.
4. Tsai, J., Wei, S., Chen, C., et al. (2022) Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio. Pharmaceuticals, 15(11):1407.
5. Chaudhary, M. A., Edmondson-Jones, M., Baio, G., et al. (2022) Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. Medical Decision Making, 0272989X221132257.
6. Boyer, M. J., Williams, C. D., Harpole, D. H., et al. (2017) Improved survival of stage I non–small cell lung cancer: a VA Central Cancer Registry analysis. Journal of Thoracic Oncology, 12(12):1814-1823.
7. Xie, J., Wu, X., Wu. J., et al. (2022) Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer. Oncology Letters, 24(6):425.
8. Lin, S., Lin, Y., Yao, L., et al. (2020) Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC. Journal of Thoracic Oncology, 15(2):248-257.
9. Qiu, L., Gao, S., Du, S., et al. (2022) Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis. Frontiersin Oncology, 29(12):974227.
10. Zhao, B., Li, H., Wu, J., et al. (2023) Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial. Journal of Thoracic Oncology, 18(1):e1-e2.
11. Chen, Y., Su, P., Huang, W., et al. (2022) The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. Scientific Reports, 12(1): 1-12.
12. Hartmaier, R. J., Markovets, A. A., Ahn, M. J., et al. (2023) Osimertinib+ Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON. Cancer Discovery, 13(1): 98.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230188
- Copyright
- 03 August 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited